Norris Medicines has informed that as per the Company's Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders framed pursuant to the Security and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2018, as amended, read with BSE circular no. LIST/COMP/O1/2019-20 dated 2nd April, 2019 regarding trading restriction period, the Trading Window for dealing in the Securities of the Company shall remain closed for the purpose of declaration of Unaudited Financial Results of the Company for the Quarter and Nine Months ended on 31st December, 2021 for all the designated persons of the Company from 01st January, 2022 to till 48 hours after the announcement of the Unaudited Financial Results of the Company.
The above information is a part of company’s filings submitted to BSE.